BIOLOG-ID
6.7.2021 17:05:10 CEST | Business Wire | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Inlog , a software company dedicated to the medical sector, have announced today a strategic interoperability partnership for their solutions.
With a market presence of more than 30 years, Inlog has developed software suites that ensure the quality and the traceability of products throughout the transfusion supply chain. These software suites are used today by nearly 250 French and international clients, including an important part of University Hospitals.
To allow blood centers and hospitals to take advantage of the RFID technology, Inlog and biolog-id are partnering to guarantee the interoperability of the Edge Track (Hemo Server) and Edge Blood (CTS Server) software with the Biolog Data System modules from the Biolog Transfusion Solution.
By combining RFID tags containing essential information of blood products, connected equipment, and a dedicated transactional and decision-making software, Biolog Transfusion Solution secures the entire blood transfusion supply chain, from the donor to the recipient. Beyond reinforcing the safety of transfused patients, the solution optimizes in real-time the local and remote inventory management of these vital therapeutic products and allows them to be attributed nominatively remotely and safely.
“We are very pleased that Inlog, who is today a reference in the field of blood supply chain management, and biolog-id collaborate to propose their users and prospects an option for strengthening traceability and securing the transfusion chain based on our RFID solution”, says Bruno Chappert, CEO at biolog-id. “This interoperability agreement will enable us to offer transfusion professionals a new feature capable of improving their efficiency, optimizing working conditions while adapting to all types of structures, and finally facilitating the rapid implementation of these software solutions”.
“We are convinced that this interoperability agreement between biolog-id and Inlog will provide healthcare and transfusion facilities with better blood product management, enhanced safety and improved traceability”, underlines David Kalfon, President at Inlog. “The numerous combined advantages of biolog-id and Inlog solutions will allow the transfusion chain professionals to rationalize their operations and optimize their costs”.
The Inlog software and Biolog Transfusion Solution will be available under different technical models to allow simple, fast and modular integration by healthcare infrastructures and to meet users’ needs.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Inlog:
Founded in 1992, Inlog is one of the leading French software companies in the field of medical informatics for laboratory analysis, traceability of blood products in healthcare facilities and the various activities of blood transfusion centers.
Inlog designs and develops a range of software for the healthcare sector whose advantages in terms of robustness, reliability and ease of configuration are distinguished by all its customers. Motivated by a new management board, Inlog is initiating an ambitious project to use new technologies into its applications to make their use even more ergonomic and intuitive.
The Inlog software suites, CE marked, are used by more than 250 Healthcare institutions in France and around the world (Germany, Switzerland, Belgium, Canada, Hong Kong, etc.), including some prestigious partners such as the Etablissement Français du Sang, the Hôpitaux Universitaires Genevois and the Flemish Red Cross.
Inlog is currently supported by the French investment fund Abénex, a major player in private equity in France.
Company URL: https://www.inlog.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom